Plasma YKL-40 in the spectrum of neurodegenerative dementia.
Aged
Aged, 80 and over
Alzheimer Disease
/ blood
Biomarkers
/ blood
Case-Control Studies
Chitinase-3-Like Protein 1
/ blood
Creutzfeldt-Jakob Syndrome
/ blood
Dementia, Vascular
/ blood
Female
Frontotemporal Dementia
/ blood
Humans
Lewy Body Disease
/ blood
Male
Middle Aged
Neurodegenerative Diseases
/ blood
Biomarker
CHI3L1
Neurodegenerative dementia
Plasma
Prion diseases
YKL-40
Journal
Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974
Informations de publication
Date de publication:
12 Jul 2019
12 Jul 2019
Historique:
received:
04
12
2018
accepted:
25
06
2019
entrez:
14
7
2019
pubmed:
14
7
2019
medline:
14
1
2020
Statut:
epublish
Résumé
Increased plasma YKL-40 has been reported in Alzheimer's disease (AD), but its levels in other neurodegenerative diseases are unknown. Here, we aimed to investigate plasma YKL-40 in the spectrum of neurodegenerative dementias. YKL-40 was quantified in the plasma of 315 cases, including healthy controls (HC), neurological disease controls (ND), AD, vascular dementia (VaD), frontotemporal dementia (FTD), sporadic Creutzfeldt-Jakob disease (CJD) and Lewy body dementia (LBD). Diagnostic accuracy in the differential diagnostic context and influence of age and gender was assessed. Highest YKL-40 levels were detected in CJD, followed by LBD, VaD, AD, FTD, ND and HC. YKL-40 was associated to age but not to sex. After controlling for age, YKL-40 was significantly elevated in CJD compared to HC (p < 0.001), ND, AD and VaD (p < 0.01) and in LBD compared to HC (p < 0.05). In CJD, YKL-40 concentrations were significantly higher at late disease stages. Plasma YKL-40 is significantly elevated in CJD regardless of clinical and genetic parameters, with moderate diagnostic accuracy in the discrimination from control cases. Our study discards a potential use of this biomarker in the differential diagnostic context but opens the possibility to be explored as a marker for CJD monitoring.
Sections du résumé
BACKGROUND
BACKGROUND
Increased plasma YKL-40 has been reported in Alzheimer's disease (AD), but its levels in other neurodegenerative diseases are unknown. Here, we aimed to investigate plasma YKL-40 in the spectrum of neurodegenerative dementias.
METHODS
METHODS
YKL-40 was quantified in the plasma of 315 cases, including healthy controls (HC), neurological disease controls (ND), AD, vascular dementia (VaD), frontotemporal dementia (FTD), sporadic Creutzfeldt-Jakob disease (CJD) and Lewy body dementia (LBD). Diagnostic accuracy in the differential diagnostic context and influence of age and gender was assessed.
RESULTS
RESULTS
Highest YKL-40 levels were detected in CJD, followed by LBD, VaD, AD, FTD, ND and HC. YKL-40 was associated to age but not to sex. After controlling for age, YKL-40 was significantly elevated in CJD compared to HC (p < 0.001), ND, AD and VaD (p < 0.01) and in LBD compared to HC (p < 0.05). In CJD, YKL-40 concentrations were significantly higher at late disease stages.
CONCLUSIONS
CONCLUSIONS
Plasma YKL-40 is significantly elevated in CJD regardless of clinical and genetic parameters, with moderate diagnostic accuracy in the discrimination from control cases. Our study discards a potential use of this biomarker in the differential diagnostic context but opens the possibility to be explored as a marker for CJD monitoring.
Identifiants
pubmed: 31299989
doi: 10.1186/s12974-019-1531-3
pii: 10.1186/s12974-019-1531-3
pmc: PMC6624942
doi:
Substances chimiques
Biomarkers
0
CHI3L1 protein, human
0
Chitinase-3-Like Protein 1
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
145Subventions
Organisme : Instituto de Salud Carlos III
ID : Miguel Servet programme - CP/00041
Organisme : Robert Koch Institute
ID : 1369-341
Organisme : Fondo Europeo de Desarrollo Regional
ID : POCTEFA 2014-2020
Références
Hum Genet. 1999 Sep;105(3):244-52
pubmed: 10987652
Inflamm Res. 2006 Jun;55(6):221-7
pubmed: 16955240
Dan Med Bull. 2006 May;53(2):172-209
pubmed: 17087877
Mov Disord. 2007 Sep 15;22(12):1689-707; quiz 1837
pubmed: 17542011
Biom J. 2008 Jun;50(3):346-63
pubmed: 18481363
Oncogene. 2009 Dec 17;28(50):4456-68
pubmed: 19767768
Brain. 2009 Oct;132(Pt 10):2659-68
pubmed: 19773352
J Neuroinflammation. 2010 Jun 11;7:34
pubmed: 20540736
Biol Psychiatry. 2010 Nov 15;68(10):903-12
pubmed: 21035623
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
J Neurol. 2011 Dec;258(12):2181-5
pubmed: 21562723
Brain. 2011 Sep;134(Pt 9):2456-77
pubmed: 21810890
Brain Pathol. 2012 Jul;22(4):530-46
pubmed: 22074331
Acta Neuropathol. 2012 Oct;124(4):517-29
pubmed: 22744790
J Alzheimers Dis. 2014;42(1):157-67
pubmed: 24820015
PLoS One. 2015 Aug 13;10(8):e0135458
pubmed: 26270969
Ann Clin Transl Neurol. 2015 Nov 20;3(1):12-20
pubmed: 26783546
Lancet Neurol. 2016 Jun;15(7):673-684
pubmed: 27068280
Neurology. 2017 Jul 4;89(1):88-100
pubmed: 28592453
J Neuroinflammation. 2017 Jun 9;14(1):118
pubmed: 28599675
Mol Neurodegener. 2017 Nov 10;12(1):83
pubmed: 29126445
Nat Rev Neurol. 2018 Mar;14(3):133-150
pubmed: 29377008
J Neurol Neurosurg Psychiatry. 2019 Jan;90(1):4-10
pubmed: 30224549
Neurology. 1993 Feb;43(2):250-60
pubmed: 8094895